Skip to main content
. 2019 Oct 8;36(12):3340–3355. doi: 10.1007/s12325-019-01105-2

Table 5.

Number (%) of subjects reporting AEIs and other AEs within 7 days post-dose 2 (i.e., vaccination day and following 6 days) using AERC in Spain

MedDRA primary system organ class (CODE) N = 139
 Preferred term (code) n %
Any 34 24.5
Any respiratory, thoracic, and mediastinal disorders (10038738) 21 15.1
 Cough (10011224)* 12 8.6
 Rhinorrhea (10039101)* 9 6.5
 Nasal congestion (10028735)* 7 5.0
 Dysphonia (10013952)* 3 2.2
 Wheezing (10047924)* 2 1.4
 Epistaxis (10015090)* 1 0.7
 Sneezing (10041232) 1 0.7
 Oropharyngeal pain (10068319)* 0 0.0
Any general disorders and administration site conditions (10018065) 11 7.9
 Injection site pain (10022086)* 7 5.0
 Pyrexia (10037660)* 6 4.3
 Chills (10008531)* 0 0.0
 Face edema (10016029)* 0 0.0
 Fatigue (10016256)* 0 0.0
 Injection site erythema (10022061)* 0 0.0
 Injection site swelling (10053425)* 0 0.0
Any infections and infestations (10021881) 5 3.6
 Conjunctivitis (10010741)* 4 2.9
 Rhinitis (10039083)* 1 0.7
Any gastrointestinal disorders (10017947) 4 2.9
 Diarrhea (10012735)* 2 1.4
 Vomiting (10047700)* 1 0.7
 Abdominal pain (10000081) 1 0.7
 Nausea (10028813)* 0 0.0
Any metabolism and nutrition disorders (10027433) 4 2.9
 Decreased appetite (10061428)* 4 2.9
Any psychiatric disorders (10037175) 4 2.9
 Irritability (10022998)* 4 2.9
Any eye disorders (10015919) 2 1.4
 Eye pruritus (10052140) 2 1.4
Any musculoskeletal and connective tissue disorders (10028395) 1 0.7
 Myalgia (10028411)* 1 0.7
 Arthropathy (10003285)* 0 0.0
Any skin and subcutaneous tissue disorders (10040785) 1 0.7
 Rash (10037844)* 1 0.7
 Rash generalized (10037858)* 0 0.0
Any immune system disorders (10021428) 0 0.0
 Anaphylactic reaction (10002198)* 0 0.0
 Hypersensitivity (10020751)* 0 0.0
Any nervous system disorders (10029205) 0 0.0
 Febrile convulsion (10016284)* 0 0.0
 Headache (10019211)* 0 0.0

AE adverse event, AEI adverse event of interest, AERC adverse event reporting card, MedDRA Medical Dictionary for Regulatory Activities [11], N total number of subjects, n number of subjects in category

*AEI